solid-phase synthesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-02 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Shortness of breath, particularly with exertion Chronic dry, hacking coughing Fatigue and weakness Chest discomfort, including chest pain Loss of appetite and rapid weight loss Pulmonary fibrosis is suggested by a history of progressive shortness of breath (dyspnea) with exertion. Sometimes fine inspiratory crackles can be heard at the lung bases on auscultation. A chest X-ray may not be abnormal, but high-resolution CT will often show abnormalities.
CO2 + glutamate + aspartate + 3 ATP + 2 NAD++ 3 H2O → urea + α-ketoglutarate + oxaloacetate + 2 ADP + 2 Pi + AMP + PPi + 2 NADH The two NADH produced can provide energy for the formation of 5 ATP (cytosolic NADH provides 2.5 ATP with the malate-aspartate shuttle in human liver cell), a net production of two high-energy phosphate bond for the urea cycle. However, if gluconeogenesis is underway in the cytosol, the latter reducing equivalent is used to drive the reversal of the GAPDH step instead of generating ATP. The fate of oxaloacetate is either to produce aspartate via transamination or to be converted to phosphoenolpyruvate, which is a substrate for gluconeogenesis.
Octopine dehydrogenase (N2-(D-1-carboxyethyl)-L-arginine:NAD+ oxidoreductase, OcDH, ODH) is a dehydrogenase enzyme in the opine dehydrogenase family that helps maintain redox balance under anaerobic conditions. It is found largely in aquatic invertebrates, especially mollusks, sipunculids, and coelenterates, and plays a role analogous to lactate dehydrogenase (found largely in vertebrates). In the presence of nicotinamide adenine dinucleotide (NADH), the enzyme catalyzes the reductive condensation of an α-keto acid with an amino acid to form N-carboxyalkyl-amino acids (called opines). The reaction reoxidizes glycolytically formed NADH to NAD+, replenishing this important cofactor used in glycolysis and allowing for the continued production of adenosine triphosphate in the absence of oxygen.
No metal-adapted endemic taxa have been documented so far. There is, however, evidence for community shifts associated with heavy metals, with lower diversity associated with contaminated sites. On the other hand, soils naturally rich in heavy metals, such as serpentine soils, do not seem to affect the diversity of ectomycorrhizal fungal communities.
Sources: en.wikipedia.org
== External links == CID 6526396 from PubChem – cefpodoxime proxetil Vantin Tablets and Oral Suspension Torpod (Torrent) Full U.S. Prescribing Information (from manufacturer's website) Simplicef (from manufacturer's website) Intas Pharmaceuticals Ltd. » Animal Health :: Intas - a leading global pharmaceutical formulation development, manufacturing and marketing company
=== July === 1 July – The ESA space telescope Euclid is launched, beginning a six-year mission to study dark energy and dark matter. 3 July – Researchers demonstrate encoding and storing data – small images – as DNA without new DNA synthesis by recording light exposure into bacterial DNA via optogenetic circuits. The 'biological camera' extends chemical and electrical interface techniques. 5 July Harvard astronomer Avi Loeb reports the possibility of a Galileo project expedition having found first interstellar material. A first evolution experiment of synthetic 'minimal cells' – JCVI-syn3B bacterial cells whose genomes were trimmed to 493 essential genes and are the smallest of any known free-living organism – shows they survive and mutate vitally with their >50% decrease in fitness to JCVI-syn1 being regained after ~2,000 generations under accelerated evolution. 6 July – A study indicates release of methane from Arctic glacial retreat will result in Arctic emissions much higher than expected.
When dried for eating, pine nuts are 2% water, 13% carbohydrates, 14% protein, and 68% fat (table). In a 100-gram (3+1⁄2-ounce) reference serving, dried pine nuts supply 2,815 kilojoules (673 kilocalories) of food energy and are a rich source (20% or more of the Daily Value, DV) of numerous dietary minerals, particularly manganese, copper, magnesium, and zinc, with substantial amounts of vitamin E, vitamin K, and the B vitamins, thiamin and niacin (table).
=== Passover === The Jewish festival of Pesach (Passover) may present problems with its obligation to eat matzah, which is unleavened bread made in a strictly controlled manner from wheat, barley, spelt, oats, or rye. In addition, many other grains that are normally used as substitutes for people with gluten sensitivity, including rice, are avoided altogether on Passover by Ashkenazi Jews. Many kosher-for-Passover products avoid grains altogether and are therefore gluten-free. Potato starch is the primary starch used to replace grains.
Epithelium Photomicrographs Histology at KUMC epithel-epith02 Simple squamous epithelium of the glomerulus (kidney) Diagrams of simple squamous epithelium Histology at KUMC epithel-epith12 Stratified squamous epithelium of the vagina Histology at KUMC epithel-epith14 Stratified squamous epithelium of the skin (thin skin) Histology at KUMC epithel-epith15 Stratified squamous epithelium of the skin (thick skin) Stratified squamous epithelium of the esophagus Microanatomy Web Atlas
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.